CONDUCTING PHARMACEUTICAL BUDGET IMPACT ANALYSES IN IRAN- IN ACCORDANCE WITH ISPOR TASK FORCE REPORT ON GOOD PRACTICE FOR BUDGET IMPACT ANALYSIS
Author(s)
Foroutan N1, Jamshidi HR1, Salamzadeh J1, Foroutan A2, Rasekh H11Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran
Presentation Documents
Increase in accessibility and affordability of healthcare services have been considered as important policy objectives since the beginning 1980s in Iran. However, current 60- 70% out-of-pocket payments creates a barrier to an equal access to quality health services especially in terms of new medicines. This affects equity issues and consequently the "health" in Iran. Currently, the quasi-government health insurance organizations considered as main budget holders or purchasers of medicines and healthcare services, do not consider comprehensive economic evaluations (Cost-effectiveness plus Budget impact analyses) for their reimbursement decisions. The present study is introducing a standard Budget Impact Analyses (BIAs) model for the first time in Iran. The main purpose is providing the healthcare budget decision makers with a practical tool improving resource allocation as well as accelerating and facilitating the process of pharmaceutical reimbursement decision making to address the problem of considerable out-of-pocket payments in Iran. In the current study, a literature systematic review was conducted on the international database Pubmed to find: 1) Standard guidelines published for BIAs and 2) Empirical studies doing Pharmaceutical BIAs, published in English language since Jan 2000 to Dec 2011. Four international standard guidelines and 22 empirical studies on BIAs were reviewed to provide a comprehensive standard model for conducting BIAs. They also include practical examples for theoretical recommendations. Moreover, semi-structured interviews were also conducted to ask policy makers opinions about the necessity of doing BIAs in Iran`s healthcare financing system as well as their opinions about the different parts of the proposed model. The final model consists of general and detailed recommendations which were extracted mainly from ISPOR task force report on Principles of Good Practice for BIAs and other reviewed guidelines. There also were recommendations made by Iranian policy makers which make the model much more practical for conducting standard BIAs in Iran.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PRM18
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Multiple Diseases